16th Annual NATA Symposium

16th Annual NATA Symposium, Prague 2015The 16th Annual NATA Symposium on Patient Blood Management, Haemostasis and Thrombosis will take place at the Prague Congress Centre in Prague, Czech Republic, on April 16-17, 2015.

The first announcement can be downloaded in PDF or Powerpoint format.

The preliminary scientific programme is now availble, and the deadline for abstract submission is December 19, 2014.

More information on the Annual NATA Symposium

Follow NATA on LinkedIn and Twitter

Join NATA's goup on LinkedIn and follow NATA on Twitter (@NATAforum) to receive the latest news on patient blood management, haemostasis and thrombosis, and to participate in discussions with colleagues in the field.
LinkedIn Group / Twitter

News from the Industry: White Paper – Red Cell Salvage: Current Status

Intraoperative Red Cell Salvage (RCS) was introduced in the early 1980s and rapidly gained clinical acceptance. Early RCS was done without cell washing, but washed RCS became the standard of care in cardiac surgery and other procedures.

RCS gained popularity because it did not carry the risk of transfusion-transmitted diseases, notably HIV and hepatitis B and C, and decreased demand for allogeneic blood. While both of these benefits are still true today, the increased safety profile of allogeneic transfusion as well as the presence of stable blood inventories have diminished their importance.

Nevertheless, strong clinical and economic reasons remain to use RCS. This white paper addresses these issues.
Read more on this

News

Akebia Announces Dosing of First Patient in Phase 2 Study of AKB-6548 in Patients with Anemia Related to Chronic Kidney Disease Undergoing Dialysis

On September 25, 2014, Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, announced that the first patient has been dosed in a Phase 2 clinical study of AKB-6548 in patients with anemia related to chronic kidney disease (CKD) who are undergoing dialysis. AKB-6548 is being developed as a once-daily, oral therapy with best-in-class potential for the treatment of anemia related to CKD.
Read more on this

From the Literature

Dec 21, 2014

Published: Dec 2014

Yu PJ, Cassiere HA, Dellis SL, et al.

Dose-dependent effects of intraoperative low volume red blood cell transfusions on postoperative outcomes in cardiac surgery patients.
J Cardiothorac Vasc Anesth 2014;28:1545-1549.

#

NATA REVIEW:
The authors retrospectively assessed the impact of intraoperative transfusion of 1 to 3 units of red blood cell...
REVIEW by:
S. Kozek-Langenecker

Published: Nov 2014

Ansell JE, Bakhru SH, Laulicht BE, et al.

Use of PER977 to reverse the anticoagulant effect of edoxaban.
N Engl J Med 2014;371:2141-2142.

#

NATA REVIEW:
This letter to the editor published in the New England Journal of Medicine reports a pharmacokinetic...
REVIEW by:
A. Godier

Published: Nov 2014

Frenette A, Bouchard J, Bernier P, et al.

Albumin administration is associated with acute kidney injury in cardiac surgery: a propensity score analysis.
Crit Care 2014;18:602.

#

NATA REVIEW:
In this retrospective study including 984 patients undergoing cardiac surgery, the authors observed that...
REVIEW by:
P. Van der Linden

Published: Oct 2014

Solbeck S, Meyer MA, Johansson PI, et al.

Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography.
Int J Cardiol 2014;176:794-799.

#

NATA REVIEW:
The authors investigated the in vitro effect of dabigatran on whole blood thromboelastography (TEG)...
REVIEW by:
B. J. Hunt

Published: Oct 2014

Kasivisvanathan R, Abbassi-Ghadi N, Kumar S, et al.

Risk of bleeding and adverse outcomes predicted by thromboelastography platelet mapping in patients taking clopidogrel within 7 days of non-cardiac surgery.
Br J Surg 2014;101:1383-1390.

#

NATA REVIEW:
Kasivisvanathan and colleagues open the door a little further to tailored antiplatelet therapy, showing good...
REVIEW by:
J. Stensballe

Published: Oct 2014

Adelmann D, Wiegele M, Wohlgemuth RK, et al.

Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry.
Thromb Res 2014;134:918-923.

#

NATA REVIEW:
Although no routine coagulation monitoring is recommended during treatment with direct factor Xa inhibitors,...
REVIEW by:
D. Faraoni